Posted by Michael Wonder on 11 Nov 2021
HSE approves reimbursement of Ajovy (fremanezumab) in migraine
11 November 2021 - Teva Pharmaceuticals Ireland has announced the approval of Ajovy (fremanezumab) 225 mg pre-filled syringe for prescription under the High Tech Drug Payments Scheme, from October 2021.
Ajovy is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month.
From 1 October 2021, Ajovy is reimbursed, under High Tech arrangements, for the prophylaxis of chronic migraine in adults who have failed three or more migraine-preventive treatments.
